Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys

Heng Li,Lei Guo,Huiwen Zheng,Jing Li,Xin Zhao,Jiaqi Li,Yan Liang,Fengmei Yang,Yurong Zhao,Jinling Yang,Mengyi Xue,Yuanyuan Zuo,Jian Zhou,Yanli Chen,Zening Yang,Yanyan Li,Weihua Jin,Haijing Shi,Zhanlong He,Qihan Li,Longding Liu
DOI: https://doi.org/10.1021/acs.bioconjchem.1c00208
IF: 4.7
2021-05-06
Bioconjugate Chemistry
Abstract:SARS-CoV-2 caused the COVID-19 pandemic that lasted for more than a year. Globally, there is an urgent need to use safe and effective vaccines for immunization to achieve comprehensive protection against SARS-CoV-2 infection. Focusing on developing a rapid vaccine platform with significant immunogenicity as well as broad and high protection efficiency, we designed a SARS-CoV-2 spike protein receptor-binding domain (RBD) displayed on self-assembled ferritin nanoparticles. In a 293i cells eukaryotic expression system, this candidate vaccine was prepared and purified. After rhesus monkeys are immunized with 20 μg of RBD–ferritin nanoparticles three times, the vaccine can elicit specific humoral immunity and T cell immune response, and the neutralizing antibodies can cross-neutralize four SARS-CoV-2 strains from different sources. In the challenge protection test, after nasal infection with 2 × 10<sup>5</sup> CCID50 SARS-CoV-2 virus, compared with unimmunized control animals, virus replication in the vaccine-immunized rhesus monkeys was significantly inhibited, and respiratory pathology observations also showed only slight pathological damage. These analyses will benefit the immunization program of the RBD–ferritin nanoparticle vaccine in the clinical trial design and the platform construction to present a specific antigen domain in the self-assembling nanoparticle in a short time to harvest stable, safe, and effective vaccine candidates for new SARS-CoV-2 isolates.This article has not yet been cited by other publications.
chemistry, multidisciplinary,biochemistry & molecular biology, organic,biochemical research methods
What problem does this paper attempt to address?
The main objective of this paper is to develop an effective vaccine platform against the novel coronavirus (SARS-CoV-2). The research team designed a self-assembling ferritin nanoparticle vaccine displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and prepared and purified this candidate vaccine in a eukaryotic expression system. By inoculating rhesus monkeys with this RBD-ferritin nanoparticle vaccine, the study found that it could induce specific humoral and T-cell immune responses, and the neutralizing antibodies could cross-neutralize four different strains of SARS-CoV-2 from different sources. In the challenge protection experiment, compared to the unvaccinated control group, the vaccinated rhesus monkeys showed significantly inhibited viral replication and milder respiratory pathological damage after high-dose nasal infection with SARS-CoV-2. These results indicate that the RBD-ferritin nanoparticle vaccine can produce effective protection in rhesus monkeys, which is of great significance for preventing SARS-CoV-2 infection. In summary, this paper aims to address the urgent need for an efficient and stable vaccine to provide comprehensive protection for humans against SARS-CoV-2 infection. It proposes a rapid and efficient vaccine platform, demonstrating good immunogenicity and protective effects, and provides an important basis for the design of further clinical trials.